

Date: October 28, 2024

Ref. No.: KDL/SE/104/2024-25

To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 543328	To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol: KRSNAA
--	--

Dear Sir/Madam,

Sub: Submission of revised Investor Presentation.

This is with reference to our submission dated October 26, 2024 bearing reference number KDL/SE/102/2024-25, where we submitted the Investor Presentation for quarter ended September 30, 2024.

In this context, it has come to our notice that there were some typographical errors on slide no. 15 containing “**Financial Performance**” of the uploaded Presentation.

Further, we are enclosing herewith the revised presentation for the Investors/Analysts on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2024.

The above error was unintentionally and we regret for the Inconvenience Caused.

Request you to take the same on your records.

Thanking you,
Yours sincerely,

For Krsnaa Diagnostics Limited



Sujoy Sudipta Bose
Company Secretary & Compliance Officer
Encl: as above

Q2FY2025 Result Presentation

One of INDIA'S LARGEST Differentiated Diagnostic Service Provider



Q2FY2025 & H1FY25 Performance

Krsnaa Diagnostics Q2FY25 – Operations at a Glance



Bharat ka Bharosemand Diagnostics

India's 1st
CAP Accreditation
in Govt. Hospital

India's 1st
NABH Accredited Tele
radiology HUB

Radiology

178
CT/MRI Centres

1,434
Tele-Reporting
Centre

Pathology

121
Processing lab

3,139
Collection
Centre

NABH

24
Accredited
centres

NABL

37
Accredited
centres



Presence In India

150+
District Location

Patient served

40Mn+
Last 3 years

Doctors Associated

500+

Strengths

~ 1.5 Lakh
CT & MRI Scans per
month

18
States & Union
Territories

CAGR

24%
Last 5 years

ICRA Rating

A
Stable

Bid Win Ratio

75%+

~ 6 lakhs
X-rays per month

Krsnaa Diagnostics H1FY25 – Financials at a Glance



In mn

Growth Momentum continues: Achieving 21% YoY Revenue Growth, 48% YoY EBITDA Strengthening & 49% YoY improvement in PAT, on account of improved footfalls across our centers and enhanced operational efficiency



Note: EBIDTA & EBIDTA Margin are before CSR & ESOP, Diluted EPS in INR

Krsnaa Diagnostics Q2FY25 – Financials at a Glance



In mn

Growth Momentum continues: Achieving 20% YoY Revenue Growth, 58% YoY EBITDA Strengthening & 87% YoY improvement in PAT on account of improved footfalls across our centers and enhanced operational efficiency

Revenue from operation

Q2FY25 | 1,863

Q2FY24 | 1,555 ▲ 20%

EBIDTA

Q2FY25 | 509

Q2FY24 | 323 ▲ 58%

PAT

Q2FY25 | 196

Q2FY24 | 105 ▲ 87%

EBIDTA Margin

Q2FY25 | 27%

Q2FY24 | 21% ▲ 655 bps

PAT Margin

Q2FY25 | 11%

Q2FY24 | 7% ▲ 376 bps

Earning Per Share




Q2FY25 | 5.92

Q2FY24 | 3.23 ▲ 84%

H1FY25 – EBIDTA Analysis




In mn



Note: Considering the nature of business, financial performance is best evaluated on an annualized basis.



Key Developments





Margin Improvement

The pricing for Apulki would be at CGHS pricing, which would enable us to improve our margins

Retail Presence

Apulki's Hospital are located at densely populated urban regions, provides opportunity to tap retail presence in these regions without incurring additional cost

Revenue Visibility


Long term revenue visibility, as the contract of Apulki is for 30 years period with option to increase additional 30 years

Expanding Services

Krsnaa will deliver a comprehensive suite of integrated diagnostic services at Apulki's facilities, enhancing access to advanced and super specialized diagnostics

Exclusive partner

Krsnaa would be their exclusive diagnostics partner



Strategic Partnership: United Imaging & Medikaa Bazaar



FINANCING TERM

Through this partnership, krsnaa has received special financing term, where-in 10% payment of equipment is done initially and remaining in staggered manner in next 6 years

EXPANSION

Targeting the establishment of over 35+ cutting-edge imaging centers across Tier-1, Tier-2 and Tier-3 cities across India



PARTNERSHIP

Medikabazaar India's largest B2B Healthcare procurement & supply-chain solutions provider.
United Imaging, a global leader in advanced imaging technologies


INVESTMENT

Partnership worth ₹300+ Crore, to make Healthcare more Accessible for all.


PAN India Presence in Radiology & Pathology



Well Diversified Regional Revenue Mix



- Highest penetration across districts with presence in 150+ out of 700+ districts; still large underpenetrated market
- Government continuous focus on improving healthcare in India and looking to partner under PPP model
- Krsnaa is already present in most of the tier I, II, III and rural areas. Krsnaa plans to leverage its extensive presence for growth



*Under Implementation

** The USG, Dexa, Mammography and TMT Centres are not marked in this map.

Project Under Implementation



Radiology Centres Under Implementation

	Total Centres	Operational	Under Implementation
Uttar Pradesh	8	5	3
Rajasthan	1	-	1
DMC	1	1	-
Mira Bhayandar	1	1	-
Maharashtra	73	40	33
Madhya Pradesh	5	-	5
Jharkhand	3	-	3
Total	92	47	45

Pathology Centres Under Implementation

	Total Centres	Operational	Under Implementation
DMC	1	1	-
BMC CC	600	473	127
Odisha CC	600	600	-
Mira Bhayandar	1	1	-
Assam	10	10	-
Assam CC	1,256	652	604
Jharkhand	1	-	1
Total	2,469	1,737	732


One of the only company in India to have 220 + CT / MRI centers installed & operational / under installation



We aim to sustain the upward trajectory of our Revenue and PAT CAGR by utilizing our existing facilities and seizing opportunities in untapped markets



Note: Our growth strategy is well defined and allows us to achieve steady state growth irrespective of dependence on individual projects like Rajasthan





Financial Performance

Financial Performance



In mn

Particulars	Q2 FY 25		Q2 FY 24		Q1 FY 25		H1 FY 25		H1 FY 24	
	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%
Revenue from operations	1,863		1,555		1,702		3,566		2,950	
Expenses										
Cost of Material Consumed	449	24%	359	23%	429	25%	878	25%	637	22%
Employee benefits expense	339	18%	263	17%	320	19%	660	19%	490	17%
Fees to hospitals and others	174	9%	203	13%	123	7%	297	8%	377	13%
Other expenses	392	22%	407	26%	388	23%	780	22%	805	27%
Total Expenses	1,354	73%	1,232	79%	1,260	74%	2,615	73%	2,309	78%
EBITDA Before CSR & ESOP	509	27%	323	21%	442	26%	951	27%	641	22%
CSR and ESOP	15	1%	5	0%	15	1%	30	1%	10	0%
EBITDA	494	26%	318	21%	427	25%	921	26%	631	21%
Less: Finance costs	64	3%	31	2%	53	3%	117	3%	50	2%
Less: Depreciation	222	12%	195	13%	215	13%	437	12%	352	12%
Add: Other income	46	2%	42	3%	73	4%	119	3%	84	3%
PBT	254	14%	134	9%	232	14%	486	14%	313	11%
Tax	58	3%	29	2%	53	3%	111	3%	62	2%
PAT	196	11%	105	7%	179	11%	375	11%	251	9%

Financial Performance



(INR In Mn)

Assets	Sep 30, 2023	Sep 30, 2024
Non-current assets		
Property, plant and equipment	5,562.30	6,863.38
Capital work-in-progress	277.42	34.76
Intangible assets	26.62	23.24
Financial assets		
Investments	2.91	2.91
Other financial assets	360.24	1233.97
Deferred tax asset (net)	15.53	24.54
Other non-current assets	209.47	589.53
Total non-current assets	6,454.49	8,772.33
Current assets		
Inventories	364.30	306.87
Financial assets		
Trade receivables	1586.65	2,434.72
Cash and cash equivalents	303.22	112.79
Bank balances other than cash and cash equivalent	1,721.99	513.44
Other financial assets	181.25	626.95
Other current assets	162.92	178.29
Total current assets	4,320.33	4,173.06
Total Assets	10,774.82	12,945.39

Liabilities	Sep 30, 2023	Sep 30, 2024
Equity		
Equity share capital	156.99	161.45
Other equity	7,395.51	8,246.17
Total equity	7,552.50	8,407.62
Liabilities		
Non-current liabilities		
Borrowings	82.50	27.50
Lease Liabilities	297.14	321.20
Other financial liabilities	276.10	160.44
Employee benefit obligations	11.22	20.53
Deferred Tax Liabilities	148.72	196.82
Other non-current liabilities	-	-
Total non-current liabilities	815.68	726.49
Current liabilities		
Financial liabilities		
Borrowings	616.64	1662.19
Lease Liabilities	95.90	149.99
Trade payables	1,108.87	928.13
Other financial liabilities	521.49	980.62
Other current liabilities	34.22	35.71
Employee benefit obligations	29.52	54.64
Total current liabilities	2,406.64	3,811.28
Total Liabilities	3,222.32	4,537.77
Total Equity and Liabilities	10,774.82	12,945.39



This presentation contains statements that are “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Krsnaa Diagnostics’ future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance.

Krsnaa Diagnostics undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For further information please contact:

Krsnaa Diagnostics

Vivek Jain, Investor Relation Head

head.investor@krsnaa.in

Contact: +91 74107 00645